Navigation Links
Oncolytics Biotech(R) Inc. Announces Unit Offering
Date:11/17/2009

ks and uncertainties include, among others, the pricing and completion of the contemplated offering, availability of funds and resources to pursue research and development projects, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, the Company's ability to successfully commercialize REOLYSIN, uncertainties related to the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.

SOURCE Oncolytics Biotech Inc.


'/>"/>
SOURCE Oncolytics Biotech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
2. Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
3. Oncolytics(R) Biotech Inc. Announces Issuance of 33rd U.S. Patent
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO Investor Forum 2009
5. Oncolytics Biotech(R) Inc. Announces Investment in Private Biotechnology Company
6. Media Advisory - Oncolytics Biotech(R) Inc. to Present at BioPartnering Europe
7. Oncolytics Biotech(R) Inc. Accelerates Warrant Expiry Date
8. Oncolytics Biotech(R) Inc. Reaches Special Protocol Assessment Agreement with the FDA on Design of Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
9. Oncolytics Biotech(R) Inc. Announces Phase 3 Update Conference Call
10. Oncolytics Biotech(R) Inc. Announces Reovirus and Cisplatin Research Supports U.S. Phase 2 Metastatic Melanoma Trial
11. Media Advisory - Oncolytics Biotech Inc. to Present at Rodman Renshaw 11th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2015)... Telbec/ - Mirego, leader in mobile strategies and solutions, is ... app extensions for the all new Apple Watch. Made in ... and MediaMiser, these extensions will reinvent the way users receive ... wrist use.  Available today in ... tactile smartwatch that makes for an excellent buddy for business, ...
(Date:4/23/2015)... 24, 2015 Ralco announced today that ... Nutrition® (ABN) for the exclusive worldwide rights to sell ... technology is a new in-line milk system that increases ... them to move supplementation milk cups within a farrowing ... “This technology lets producers get Birthright™ milk to the ...
(Date:4/23/2015)... Fla. , April 23, 2015 BioTE ... releases his book "Age Healthier Live Happier - Avoiding ... off the Age Management Medicine Group Conference at JW ... 26, 2015. ",Age Healthier Live Happier, is ... to avoid over-medication and searching for a higher quality ...
(Date:4/23/2015)... 2015 Follow us on ... series of genetic tests that determine individual susceptibility ... disease, Huntington's disease, and Alzheimer's disease. Predictive diagnostics ... and interaction in diseased tissue/cells to understand and ... the response to treatment, such as in the ...
Breaking Biology Technology:Familiprix, OMSignal and MediaMiser apps available today for Apple Watch 2Ralco Acquires License to Birthright™ Moveable Milk Cup 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 2Release and Book Signing of BioTE Medical President Gary Donovitz M.D. 'Age Healthier Live Happier' at Age Management Medicine Group (AMMG) Conference 3Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 2Increasing Disease Prevalence & Focus on Preventive Healthcare Drive the Predictive Diagnostics Market, According to a New Report by Global Industry Analysts, Inc. 3
... Scientists engaged in biological research and drug discovery are ... BioInformatics, LLC ( www.gene2drug.com ), the premier research ... released preliminary data from the company,s newest report ... Science Suppliers. In this report, we set out ...
... LOUIS, Feb. 11 Sigma-Aldrich, a leading Life,Science and High ... by 6% to $0.68 from $0.64 in the same quarter ... $510 million in the fourth quarter 2008 declined by 4%,compared ... fourth,quarter grew 3% from a year ago. Fourth quarter organic ...
... Development for Chronic Pain IndicationsLA JOLLA, Calif., Feb. ... TPTX ) today announced that oral administration of ... and well-tolerated in healthy male and female subjects ... successful completion of this Phase I trial demonstrating ...
Cached Biology Technology:Life Science Labs Reacting to the Economic Crisis 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 2Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 3Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 4Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 5Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 6Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 7Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 8Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 9Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 10Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 11Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 12Sigma-Aldrich (Nasdaq: SIAL) Reports Fourth Quarter Diluted EPS of $0.68. Ends 2008 With Record Sales and Earnings and Raises Quarterly Cash Dividend by 11.5%. Provides Outlook for 2009. 13First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 2First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 3First Multiple Dose Clinical Trial of TorreyPines Therapeutics' Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated 4
(Date:4/20/2015)... 20, 2015 The announcement comes ... Glenbeigh Records Management (GRM), Ireland,s foremost ... Bank. Having built up an impressive track record of clients ... player within the records management sector in Dubai ... is GCC staffbase and employ a further eight staff members ...
(Date:4/13/2015)... 2015 According to a ... Market Forecast & Opportunities, 2020", the global biometrics market ... 14% till 2020. The biometrics market is garnering ... and review of biometric management systems. The constant ... with greater efficiency, are resulting in increasing installation ...
(Date:4/8/2015)... , April 8, 2015  Infinisource, a ... and services, and Morpho, a leading supplier of ... to produce the market,s most advanced biometrically-enabled time ... iSolved NXG time clock is setting a bold, ... labor data for the small and mid-size employer. ...
Breaking Biology News(10 mins):Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 2iSolved Time Clock Offers Unmatched Accuracy due to Morpho Biometrics 3
... by the Duke-NUS Graduate Medical School (Duke-NUS) in Singapore ... key protein linked to stem cell-like behavior in terminal-stage ... drugs that may extend the survival of these patients. ... Proceedings of the National Academy of Sciences , ...
... to reduce by more than half the time it takes ... researchers in Penn State,s College of Agricultural Sciences. The finding ... foodborne illness, allowing epidemiological investigators to identify the exact strains ... more quickly find -- and eliminate -- the source of ...
... long been used for various purposes, like cleaning wastewater at ... handcrafted wickerwork, as means of nutrition and, in traditional medicine, ... Fraunhofer Institute for Building Physics IBP in Valley now want ... to wit, for the insulation of outer walls or ...
Cached Biology News:Singapore research team identifies new drug target in deadly form of leukemia 2Researchers develop a faster method to identify Salmonella strains 2Researchers develop a faster method to identify Salmonella strains 3Using cattails for insulation 2Using cattails for insulation 3